The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAVI Global Trust Regulatory News (AGT)

Share Price Information for AVI Global Trust (AGT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 243.00
Bid: 242.00
Ask: 243.00
Change: -0.50 (-0.21%)
Spread: 1.00 (0.413%)
Open: 243.50
High: 243.50
Low: 242.50
Prev. Close: 243.50
AGT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Monthly Factsheet

15 May 2024 17:19

RNS Number : 6141O
AVI Global Trust PLC
15 May 2024
 

 

AVI GLOBAL TRUST PLC

 

Monthly Update

 

AVI Global Trust plc (the "Company") presents its Update, reporting performance figures for the month ended 30 April 2024.

 

This Monthly Newsletter is available on the Company's website at:

https://www.assetvalueinvestors.com/content/uploads/2024/05/AGT-APR-2024.pdf

 

Performance Total Return

 

This investment management report relates to performance figures to 30 April 2024.

 

Total Return (£)

Month

Calendar Yr

to date

1Y

3Y

5Y

10Y

AGT NAV

0.8%

6.0%

25.4%

27.8%

72.0%

171.3%

MSCI ACWI

-2.4%

6.5%

17.9%

25.3%

63.5%

196.4%

MSCI ACWI ex US

-0.9%

4.7%

9.7%

11.7%

33.1%

98.2%

 

Manager's Comment

 

AVI Global Trust (AGT)'s NAV increased +0.8% in April

 

Hipgnosis Songs Fund ("SONG") was the standout performer, adding an estimated +277bps to your company's NAV. We expand on this further below but we believe such returns are testament to the value that can be added through activism, and AVI's positioning in the London-listed closed-end fund market.

 

Performance from the rest of the portfolio was modest in a tougher month for equities. News Corp cost us -58bps as the discount widened to 42% from 38%, whilst FEMSA and IAC detracted -39bps and -31bps, respectively.

 

Hipgnosis Songs Fund

On 18-Apr-24, Concord - a music rights firm backed by Apollo - announced a binding offer for SONG at a price of $1.16-$1.18 per share. Blackstone, the majority owner of Hipgnosis Songs Management (HSM, the Manager of SONG) responded just two days later with a bid of $1.24. Concord then pipped this by 1c, followed by Blackstone raising their bid to $1.30. Given Concord have subsequently confirmed they will not be improving their offer, it seems highly likely that Blackstone will prevail with their $1.30 bid which represents a premium of +47% to the undisturbed share price.

This marks the end of a highly successful investment for AGT, in which we played a key role in fighting off the proposed related-party sale of a portion of SONG's catalogues and also making the case against the company continuing in its present form. Resolutions proposing each matter were heavily defeated at shareholder meetings. With two directors resigning on the eve of the AGM and the then-Chairman suffering a resounding vote against his re-election, we and other shareholders engaged with the remaining rump to push for the appointment of two new directors - Robert Naylor and Francis Keeling - who had just stepped down from SONG's peer company, Round Hill Music Royalty Fund, following its acquisition by Concord. Both were appointed with Robert immediately installed as Chairman. Christopher Mills then joined the Board a month later.

The events and news-flow since then are beyond the word count constraints of this newsletter but suffice to say, we are happy with an outcome that has not only generated a very strong return for AGT's shareholders but has demonstrated again both the value of shareholder activism and the critical importance of having the right people on Boards. The new directors joined the company at a time of crisis and engineered an excellent outcome for shareholders in a timeframe few would have felt possible at the time of their appointment. With no viable future as an ongoing listed vehicle, the key task facing the new appointees was how best to generate competitive tension in a situation where, under the terms of the Investment Management Agreement, the Manager had a call option allowing them to purchase the portfolio in the event of their termination. The investigatory work conducted by the Board and their advisors, some of the fruits of which were made public, led to an understandable perception that there existed more than sufficient grounds to terminate the Manager "for cause", which would invalidate the option.

We think it likely that this, alongside other measures introduced by the newly-reconstituted Board, gave Concord the confidence to make their initial bid and resulted in a higher price ultimately being achieved for the company than would otherwise have been the case. We applaud the new directors' fortitude and shrewd handling of a highly complex situation.

 

Princess Private Equity

 

Our Aug-23 newsletter discussed (and praised) Pantheon International ("PIN")'s new capital allocation policy and associated large share buyback programme, and its wider implications for the listed private equity and broader alternatives sectors. We await the finer details of the policy, set to be announced within the next few weeks, with interest.

 

One of our other large positions in the listed private equity sector, Princess Private Equity ("PEY"), recently followed suit with a clearly defined capital allocation policy of its own that was met with a warm reception from industry participants. One prominent sell-side analyst correctly identified it as "the most structured capital allocation policy…in the listed PE space" and "reflect[ing] the inconvenient truth for many managers that buying back shares when the shares are on wide discounts is likely to be considerably more accretive for shareholders than making new investments."[1]

PEY is a London-listed closed-end fund that offers access to direct private equity investments made by Partners' Group, the Swiss-listed private capital manager with $150bn of assets under management. PEY's new policy will see 75% of free cash flow steered to buybacks when PEY's discount is wider than 30%; 50% when the discount is between 20% and 30%; and with the Board emphasising that they reserve the right to buy back shares at discounts below 20%. This share repurchase programme is additive to the existing high dividend policy that targets a total annual pay-out (paid in two semi-annual instalments) equivalent to 5% of the previous year's closing NAV. At the current share price, this not only represents an attractive yield on share price of 6.7% but is materially accretive for shareholders given it represents a return of capital at a zero discount (versus PEY's current 25% discount). Recognising their importance to shareholders, the buyback programme ranks behind these dividend payments (i.e., the free cash flow metric used to determine the allocation to buybacks is net of dividends).

PEY's dividend yield had helped keep its discount relatively narrow until cash outflows from their FX-hedging programme forced a suspension of the dividend in late-2022. We built our position - reaching a 10% stake - in the wake of the sell-off that followed, sensing an opportunity to engage with the Board and Manager to resolve various governance issues we believed to be the underlying root cause of the dividend suspension and the botched shareholder communications surrounding it.

Although the dividend was soon restored, the then-Chairman and the Partners Group representative on the Board resigned on the eve of the AGM that followed these events, thus avoiding their public defenestration at the hands of shareholders. Following further engagement with the remaining directors, we were pleased with the appointment of private equity veteran Peter McKellar as Chairman in Nov-23 and were confident his vast experience of the listed private equity market would be of huge benefit to the company. While the new capital allocation policy is a critically important development (and we also welcome the strengthening of the Board with further appointments, and the proposed renaming of the Company to capitalise on the Manager's profile), there remains more work to be done to better align fees with shareholder outcomes, improve disclosure, and re-invigorate investment returns.

As with our investment in SONG described above, we believe the changes at PEY demonstrate the value that can be added through shareholder engagement and further emphasise the importance of a strong Board.

While there are several reported exit processes under away at some of PEY's larger investments, we were pleased to see one that had not previously been flagged come through when it was announced in early-April that the company's second-largest holding, building products specialist SRS Distribution, is to be acquired by home improvement behemoth Home Depot at a valuation almost +30% above where it was carried in PEY's previous NAV.

Contributors / Detractors (in GBP)

 

Largest Contributors

1- month contribution

bps

% Weight

Hipgnosis Songs

277

8.2

Symphony International Holdings

30

2.3

GCP Infrastructure Inv

14

2.6

Nihon Kohden

11

2.7

Pantheon International

9

3.8

 

Largest Detractors

1- month contribution

bps

% Weight

News Corp

-58

6.6

FEMSA

-39

4.4

IAC

-31

2.8

Schibsted ASA 'B'

-28

4.0

KKR

-20

2.9

 

 

Link Company Matters Limited

Corporate Secretary

 

15 May 2024

 

LEI: 213800QUODCLWWRVI968

 

The content of the Company's web-pages and the content of any website or pages which may be accessed through hyperlinks on the Company's web-pages, other than the content of the Newsletter referred to above, is neither incorporated into nor forms part of the above announcement.


1 J.P.Morgan Cazenove, Investment Companies Daily, 25-Mar-24

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DOCMZGMKVKVGDZM
Date   Source Headline
28th May 20243:48 pmRNSNet Asset Value(s)
24th May 20243:08 pmRNSNet Asset Value(s)
23rd May 20245:14 pmRNSTransaction in Own Shares
23rd May 20242:32 pmRNSNet Asset Value(s)
22nd May 202412:36 pmRNSNet Asset Value(s)
21st May 20245:45 pmRNSTransaction in Own Shares
21st May 20244:48 pmRNSHolding(s) in Company
21st May 20241:11 pmRNSNet Asset Value(s)
20th May 20241:08 pmRNSNet Asset Value(s)
17th May 202412:50 pmRNSNet Asset Value(s)
16th May 20245:55 pmRNSTransaction in Own Shares
16th May 20242:44 pmRNSHolding(s) in Company
16th May 20241:34 pmRNSNet Asset Value(s)
15th May 20245:43 pmRNSTransaction in Own Shares
15th May 20245:19 pmRNSMonthly Factsheet
15th May 20241:20 pmRNSNet Asset Value(s)
14th May 20241:05 pmRNSNet Asset Value(s)
13th May 20241:00 pmRNSNet Asset Value(s)
10th May 20244:43 pmRNSHolding(s) in Company
10th May 20241:35 pmRNSNet Asset Value(s)
9th May 20245:55 pmRNSTransaction in Own Shares
9th May 202412:46 pmRNSNet Asset Value(s)
8th May 20241:27 pmRNSNet Asset Value(s)
7th May 20241:18 pmRNSNet Asset Value(s)
3rd May 20242:08 pmRNSNet Asset Value(s)
2nd May 20245:43 pmRNSTransaction in Own Shares
2nd May 20241:55 pmRNSNet Asset Value(s)
1st May 20241:39 pmRNSNet Asset Value(s)
1st May 20247:00 amRNSTotal Voting Rights
30th Apr 202412:30 pmRNSNet Asset Value(s)
29th Apr 20241:34 pmRNSNet Asset Value(s)
26th Apr 202412:06 pmRNSNet Asset Value(s)
25th Apr 20241:57 pmRNSNet Asset Value(s)
24th Apr 202412:34 pmRNSNet Asset Value(s)
23rd Apr 20241:00 pmRNSNet Asset Value(s)
22nd Apr 202412:54 pmRNSNet Asset Value(s)
19th Apr 20245:35 pmRNSTransaction in Own Shares
19th Apr 20243:39 pmRNSNet Asset Value(s)
19th Apr 20247:00 amRNSCompliance with Market Abuse Regulation
18th Apr 20245:40 pmRNSTransaction in Own Shares
18th Apr 202412:18 pmRNSNet Asset Value(s)
17th Apr 202412:24 pmRNSNet Asset Value(s)
16th Apr 202412:31 pmRNSNet Asset Value(s)
15th Apr 202412:44 pmRNSNet Asset Value(s)
12th Apr 20245:30 pmRNSTransaction in Own Shares
12th Apr 20242:09 pmRNSNet Asset Value(s)
11th Apr 20245:49 pmRNSTransaction in Own Shares
11th Apr 202412:59 pmRNSNet Asset Value(s)
10th Apr 20245:44 pmRNSTransaction in Own Shares
10th Apr 20241:01 pmRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.